Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
AbstractPurpose of ReviewTo critically review the potential clinical applications of prostate-specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC).Recent FindingsRadioactive probes targeting PSMA hold promise in several malignancies in addition to prostate cancer, owing to the expression of PSMA by tumor neovasculature. The majority of clear cell RCCs (ccRCC), the most malignant RCC subtype, express PSMA on tumor-associated neovasculature. The endothelium of less aggressive RCC subtypes is PSMA positive in a lower, but still significant percentage of cases. PSMA might therefore represent an interesting theragnostic target in RCC.SummaryThe preliminary data available suggest a potential role for PSMA-targeting radiopharmaceuticals in complementing conventional imaging for staging ccRCC patients at risk of nodal involvement and oligometastatic disease. Additional applications of PSMA imaging may be the selection and the response assessment of patients receiving anti-angiogenic treatments. The effectiveness of PSMA-targeting radionuclide therapy should also be investigated.
This article summarizes the associations between miR-429 and malignant tumors as well as potential action mechanisms. miR-429 has a potential to be used in the future as a biomarker for the diagnosis, treatment and prognosis of certain cancers. PMID: 31884798 [PubMed - as supplied by publisher]
CONCLUSIONS: The single-port approach has advantages as easier surgical planning and transition for combined and multi-quadrants surgeries: faster recovery, minimal postoperative pain and need for opioids, and excellent cosmetic outcome. We suggest that combined procedures should be performed only in high volume institutions by surgeons with vast experience in robotic surgery in selected patients. PMID: 31864774 [PubMed - as supplied by publisher]
Conclusions223RaCl2 has demonstrated “proof of concept” for use of TAT in cancer in clinical practice. The efficacy and safety of223RaCl2 monotherapy have been demonstrated in mCRPC, and223RaCl2 combination therapies are under investigation in various tumours. TAT has broad applicability across tumour types.
For prostate cancer (PCa), we review racial differences in incidence, androgen pathways, growth factors, tumor location, rate of definitive treatment, and outcomes. We review the effect of race on risk-stratification and discuss studies of active surveillance in the African American (AA) population. For bladder cancer, race- and gender- associated differences in incidence, sex hormone pathways. For renal cell carcinoma (RCC), disparities in incidence, genetic factors, tumor pathology, time to presentation, and disease specific survival have been observed.
Conclusion: It was shown that metastasectomy would have additional contribution on prognosis in patients with prolonged DFI, unilateral metastases, and less than 3 radioimagistic detectable metastases. We presented our experience on pulmonary metastasectomy in urogenital tumors.
ConclusionsThe continuous incorporation of clinical data, further ML and DL algorithm retraining, and generalizability of models will augment the prediction accuracy and enhance individualized medicine.
Abstract Skeletal metastases are common in genitourinary malignancies-including prostate cancer, renal cell carcinoma, and urothelial cancer-and portend significant morbidity and poor prognosis. The presence of skeletal metastases can result in decreased quality of life and increased morbidity. Strategies can be employed to prevent bone-related complications including lifestyle modifications and dietary supplementation. Additionally, pharmacologic agents exist to prevent bone loss and may be appropriate for patients at high risk of fragility-related or skeletal complications, such as pathologic fracture related to...
AbstractBackgroundDigital biomarkers allow for continuous remote patient monitoring and will potentially change the way healthcare is provided and clinical trials are designed. We conducted a study to identify current preferences and interest in digital biomarkers in patients with advanced urological cancers.MethodsWe included 80 patients undergoing systemic therapy for advanced urologic malignancies at our institution. A questionnaire was developed to survey the current access to online information and digital technologies and to rate preferences on a scale from 1 (does not apply) to 5 (fully applies). Statistical analysi...
AbstractWe prospectively validate the efficacy of the frailty discriminant score (FDS) in individuals with urological cancers, as there has been growing importance in evaluating frailty in clinical practice. A prospective, multicenter study was conducted from February 2017 to April 2019. We enrolled 258 patients with urological cancers and 301 community-dwelling participants who were assessed for frailty. Frailty was assessed using FDS that includes ten items, such as physical, mental, and blood biochemical tests. The primary outcome was the non-inferiority (margin 5%) of FDS in discriminating patients with urological canc...
CONCLUSION: Immunotherapy is a key treatment in kidney and bladder cancer. In the future, the identification of predictive markers should allow us to better select patients responding to immunotherapy. PMID: 31477432 [PubMed - as supplied by publisher]